Board of Directors

William V. Skillman. See information in "Management Team". Bill serves as the Chairman of the Board as well as President and CEO of Velico Medical

Frank A. Corvino is a seasoned healthcare executive who recently retired as President and Chief Executive Officer of Greenwich Hospital (a member of the Yale New Haven Health System) in Greenwich, Connecticut. Mr. Corvino was named to his position in 1991, a few years after joining the hospital in 1988 as Senior Vice President and Chief Operating Officer. In addition to executive management of the hospital, Mr. Corvino led fund raising solicitations, raising over $300 million dollars. Under Mr. Corvino’s leadership, Greenwich Hospital  became a premier healthcare facility with a national reputation for clinical excellence, patient satisfaction and safety. Prior to joining Greenwich Hospital, Mr. Corvino was an executive vice president at Our Lady of Mercy Medical Center in the Bronx, N.Y. Mr. Corvino earned a B.S. in Pharmacy at Fordham University and an M.S. in Pharmacy Administration at St. John’s University. He serves on the boards of the Connecticut Hospital Association; Greenwich Emergency Medical Services; HealthEquity, Inc., a publicly-traded healthcare finance technology company; the Connecticut Community Bank, N.A. and Cabrini of Westchester. Mr. Corvino has received numerous awards, including the Ellis Island Medal of Honor and the Malcolm T. MacEachern CEO Award, and has been honored by the Columbus Citizen’s Foundation and many other organizations.


Roger Y. Dodd, Ph.D. is an internationally acclaimed leader in the field of transfusion medicine and has significant experience and expertise in the area of biomedical research and development. Dr. Dodd recently retired as Vice President, Biomedical Research and Development at the Jerome H. Holland Laboratories of the American Red Cross.  His tenure with the American Red Cross extended for more than 40 years.  Dr. Dodd was responsible for American Red Cross research programs supporting its blood program.  He has more than 175 publications and has edited three books on transfusion transmitted infections. He has been an Advisor to the World Health Organization and he serves on the editorial boards of Transfusion and Transfusion Medicine.  Dr. Dodd is a past-president of the American Association of Blood Banks and currently serves on the Board of International Society of Blood Transfusion as Secretary General.  He has received the Morten Grove-Rasmussen and Emily Cooley Memorial Awards from the AABB; a Tiffany Award from the American Red Cross; and the John Snow award from the American Public Health Association.  Dr. Dodd holds a Bachelor of Science degree with Honors in Biochemistry from the University of Sheffield (England).  He earned a Ph.D. in Immunology from George Washington University.


Rolf Kaelin has served as a director since June 2001. He has more than 20 years of international experience in investment banking and asset management.  Until April 2013, Mr. Kaelin was a director of ProgressNow! invest AG, a Swiss venture capital firm and our largest stockholder.  He is also a founder and Managing Director of Kaelin Management AG, a Swiss management firm.  From 1995 to 1998, Mr. Kaelin served as Head of Corporate Development for Liechtenstein Global Trust.  Mr. Kaelin is a graduate of executive studies at the Hendon College, England and completed the Advanced Management Program at The Wharton School of the University of Pennsylvania.



Robert W. Middleton is a co‑founder of the Company and has served as a director since May 1991. Most recently, he was Managing Director, The Middleton Group Division, Source Capital Group, Inc.  His immediately prior position was Chairman of The Middleton Group, LLC, an affiliate of Gemini Financial Corporation.  Mr. Middleton’s other prior positions, all involving investment banking for medical and high technology companies, include those with Trautman Kramer & Company, Inc., C. L. King & Associates, Inc. and Barclay Investments, Inc.  Prior to these activities, he was a General Partner with Fahnestock & Company and held various positions with Burgess & Leith, Inc., including Senior Vice President and director.  He attended Princeton University.


John A. Sedor has more than 30 years of proven leadership in the plasma, global pharmaceutical, biopharmaceutical, consumer product and generic drug industries. Mr. Sedor is recognized for his entrepreneurial leadership approach to turnaround and rapid growth environments, leveraging strategic creativity, consumer and professional customer insight, merger and acquisition experience and operational expertise.  Prior to his current role as Chairman & Chief Executive Officer at Rodes Inc., Mr. Sedor most recently served as President, Chief Executive Officer and a Director of Cangene Corporation, one of the world’s leading biopharmaceutical companies in the development, manufacture and commercialization of therapies targeting infectious disease, hematology/oncology and transplantation. Under his leadership, Cangene was acquired by Emergent BioSolutions in February 2014.  Prior to Cangene, he served as President, Chief Executive Officer and Director of CPEX Pharmaceuticals, Inc., a specialty drug delivery pharmaceutical company, managing its spin-off from Bentley Pharmaceuticals, Inc. Prior to CPEX, he was President of Bentley Pharmaceuticals which expanded its nanotechnology programs and added more than 20 new product approvals in the European market under his leadership.  In 1996, John created Centeon LLC to develop and commercialize plasma protein biotherapeutics.  Other previous roles include President of Sandoz Inc. (now part of Novartis), and various senior positions at Verion, Rorer Pharmaceutical Co., Revlon Health Care Group and Armour Pharmaceutical Company.  Mr. Sedor holds a Bachelor of Science in Pharmacy/Chemistry from Duquesne University and completed advanced training in marketing and strategy at Harvard University and the Kellogg Graduate School of Management.


Thomas P. Stossel, M.D. has served as a director since April 2000. He is the American Cancer Society Clinical Research Professor of Medicine at the Harvard Medical School as well as Senior Physician in the Hematology Division at Brigham & Women’s Hospital in Boston.  For his contributions to blood research, Dr. Stossel has been elected to the National Academy of Sciences, The Institute of Medicine, and the American Academy of Arts and Sciences.  He has been awarded honorary M.D. degrees from the University of Linköping, Sweden, and the University of Geneva, Switzerland, and was awarded the American Society of Hematology’s Damashek and Thomas Prizes. Dr. Stossel is the author of numerous scientific publications and of two hematology textbooks.  He was Editor-in-Chief of the Journal of Clinical Investigation and is currently Editor-in-Chief of Current Opinion in Hematology.  He served on the Scientific Advisory Boards of Biogen, Inc. and Dyax Corp and is founding scientist and a director of Critical Biologics Corporation.  Dr. Stossel earned an A.B., summa cum laude, from Princeton University where he received the Kennedy and Class of 1868 Prizes for English Literature, and received his M.D., cum laude, and the Resnick Prize for student research from Harvard Medical School.